Market Overview

UPDATE: Piper Jaffray Downgrades XenoPort to Neutral on Drug Commercialization Delays

Related XNPT
Benzinga's M&A Chatter for Monday May 23, 2016
Mid-Afternoon Market Update: KLX Drops On Q1 Results; Resource America Shares Spike Higher

Piper Jaffray reduced its rating on XenoPort (NASDAQ: XNPT) from Overweight to Neutral with a reiterated $12 price target.

Piper Jaffray said, "Given the long road ahead for '829, our cautious view on the prospects for a partnership for '829 or outright sale of the company in the near-term and the lack of visibility on cash generation (i.e., continued lackluster prescription trends for Horizant and niche-like potential for arbaclofen placarbil for spasticity), we believe upside for XNPT shares is limited in the context of an enterprise value of $430M."

XenoPort closed at $11.91 on Thursday.

Latest Ratings for XNPT

Jan 2016Credit SuisseMaintainsUnderperform
Jan 2016Credit SuisseInitiates Coverage onUnderperform
Jan 2015JefferiesMaintainsBuy

View More Analyst Ratings for XNPT
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (XNPT)

View Comments and Join the Discussion!